/ Ways2Capital : Zydus Receives Final Approval From The USFDA For Two ANDAs ~ Ways2Capital|Stock Tips|Stock Market Tips|Intraday Stock Tips|Stock Trading Tips|NSE BSE Tips

Friday, 17 February 2017

Zydus has received final approval from the USFDA for Fluconazole Tablets USP and Clobetasol Propionate Spray.The Fluconazole Tablets USP is in strengths of 50 mg, 150mg and 200 mg; and Clobetasol Propionate Spray of 0.05%.

The Fluconazole Tablets USP are used to treat fungal infections, and will be produced at the group’s formulations facility at Baddi. Clobetasol Propionate Spray is used in the treatment of various skin disorders and will be manufactured at the group’s dedicated Topical plant at Changodar, Ahemdabad.

The group now has more than 105 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Cadila Healthcare Ltd is currently trading at Rs 448.5, up by Rs 19.05 or 4.44% from its previous closing of Rs 429.45 on the BSE. The scrip opened at Rs 446 and has touched a high and low of Rs 460 and Rs 438.1 respectively. So far 10259486(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs 43964.63 crore.

The BSE group 'A' stock of face value Rs 1 has touched a 52 week high of Rs 439.8 on 16-Feb-2017 and a 52 week low of Rs 305 on 12-Apr-2016. Last one week high and low of the scrip stood at Rs 439.8 and Rs 356.3 respectively.The promoters holding in the company stood at 74.79 % while Institutions and Non-Institutions held 17.18 % and 8.03 % respectively. The stock is currently trading above its 100 DMA.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007